InnoCare and Eli Lilly Sign 3.35 Billion Deal
Chinese drugmaker InnoCare Pharma entered into a research collaboration and licensing agreement with Eli Lilly worth up to 3.35 billion dollars. The partnership involves developing new medicines across up to five targets.
Xurve View
Insights:
Xurve View
InnoCare Pharma signed a research and licensing agreement with Eli Lilly & Co valued at up to $3.35B in China during Thursday's afternoon session. The partnership expands the Beijing-based drugmaker's pipeline across five oncology and autoimmune targets. The agreement comes as major pharmaceutical firms increasingly partner with Asian biotech platforms to source novel clinical candidates.
